University of Georgia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Tag: Plasmodium

Benzo-ring modification on Malaria Box hit MMV008138: effects on antimalarial potency and microsomal stability

Donna Huber on August 15, 2025

graphical abstract

Tetrahydro-β-carboline 1 (MMV008138) controls growth of asexual blood-stage Plasmodium falciparum by inhibiting IspD, an enzyme in the MEP pathway for synthesis of a critical metabolite, isopentenyl pyrophosphate (IPP). We have previously investigated the structure activity relationship (SAR) of three of its four rings (B, C, and D). In this report we investigate the SAR of the benzo- (i.e. A-ring) of 1, with the goal of increasing its in vitro antimalarial potency and metabolic stability. As in our previous studies of the B- and C-ring substitution, extreme sensitivity to substitution was also seen in the benzo-ring. In total, 19 benzo-ring substitution variants of 1 were prepared. When tested against multidrug-resistant (Dd2 strain) P. falciparum, only three derivatives (20a, c, d) possessed asexual blood stage (ABS) activity with EC50 values within 3-fold of the parent. As hoped, one analog (20c) showed a marked improvement in microsomal stability. However, this improvement unfortunately did not improve plasma exposure relative to 1, and did not lead to oral efficacy in a mouse model of malaria.

Maryam Ghavami, Haibo Li, Lixuan Liu, Joshua H Butler, Sha Ding, Grant J Butschek, Reagan S Haney, R McAlister Council-Troche, R Justin Grams, Emilio F Merino, Jennifer M Davis, Maxim Totrov, Maria B Cassera, Paul R Carlier. RSC Med Chem. 2025 Aug 15. doi: 10.1039/d5md00439j.

HaloPROTAC3 does not trigger the degradation of the halotagged parasitophorous vacuole membrane protein UIS4 during Plasmodium liver stage development

Donna Huber on May 26, 2025

FIgure 1 Host-driven targeted degradation of a Plasmodium liver stage PVM protein using HaloTag technology.
Host-driven targeted degradation of a Plasmodium liver stage PVM protein using HaloTag technology.

Targeted protein degradation (TPD) is a novel strategy for developing therapeutics against pathogens. Prior to causing malaria, Plasmodium parasites replicate within hepatocytes as liver stages, surrounded by a parasitophorous vacuole membrane (PVM). We hypothesized that TPD can be employed to trigger host-driven degradation of essential liver stage PVM proteins and lead to parasite death. To explore this, we took advantage of the proteolysis-targeting-chimera HaloPROTAC3, a molecule that recruits the host von Hippel-Lindau (VHL) E3 ligase to the HaloTag (HT). Parasites expressing HT fused to the host cytosol-exposed domain of the PVM protein UIS4 (UIS4-HT) were generated in Plasmodium berghei and Plasmodium cynomolgi, but only P. berghei UIS4-HT enabled productive liver stage infection experiments in vitro. Although HaloPROTAC3 triggered the degradation of HT proteins in host cells, it had no impact on the survival of P. berghei UIS4-HT liver stages. Furthermore, HaloPROTAC3 bound to P. berghei UIS4-HT but did not recruit VHL or trigger ubiquitination of the PVM. Overall, although this study did not establish whether host-driven TPD can degrade Plasmodium PVM proteins, it highlights the challenges of developing TPD approaches against novel targets and offers insights for advancing this therapeutic strategy against pathogens.

Melanie Lam, Alexandra Probst, Laura Torres, Ashley A Lantigua, Matthew E Fishbaugher, Jyothsna R Kumar, Manuel Saldivia, Allison Torres, Shreeya Hegde, Maya Aleshnick, Charlie Jennison, Sarah G H Roberson, Chester J Joyner, Ashley M Vaughan, Brandon K Wilder, Carole Manneville, Erika L Flannery, David Marcellin, Beat Nyfeler, Zacharias Thiel, Sebastian A Mikolajczak, Anke Harupa, Gabriel Mitchell. Sci Rep. 2025 May 26;15(1):18323. doi: 10.1038/s41598-025-98257-9.

Discovery and optimization of a novel carboxamide scaffold with selective antimalarial activity

Donna Huber on March 28, 2025

graphical abstract

Artemisinin combination therapies (ACTs) are critical components of malaria control worldwide. Alarmingly, ACTs have begun to fail, owing to the rise in artemisinin resistance. Thus, there is an urgent need for an expanded set of novel antimalarials to generate new combination therapies. Herein, we have identified a 1,2,4-triazole-containing carboxamide scaffold that, through scaffold hopping efforts, resulted in a nanomolar potent deuterated picolinamide (110). The lead compound of this class (110) displays moderate aqueous solubility (13.4 μM) and metabolic stability (CLintapp HLM 17.3 μL/min/mg) in vitro, as well as moderate oral bioavailability (%F 16.2) in invivo pharmacokinetic studies. Compound 110 also displayed activity against various P. falciparum isolates with different genetic backgrounds and a slow-to-moderate rate of killing (average parasite reduction ratio 2.4), making the series appealing for further development.

Alicia Wagner, Roger Trombley, Maris Podgurski, Anthony A Ruberto, Meng Cui, Caitlin A Cooper, William E Long, Gia-Bao Nguyen, Adriana A Marin, Sarah Lee Mai, Franco Lombardo, Steven P Maher, Dennis E Kyle, Roman Manetsch.Eur J Med Chem. 2025 Mar 28:291:117572. doi: 10.1016/j.ejmech.2025.117572.

Type I interferons induce guanylate-binding proteins and lysosomal defense in hepatocytes to control malaria

Donna Huber on March 25, 2025

graphical abstractPlasmodium parasites undergo development and replication within hepatocytes before infecting erythrocytes and initiating clinical malaria. Although type I interferons (IFNs) are known to hinder Plasmodium infection within the liver, the underlying mechanisms remain unclear. Here, we describe two IFN-I-driven hepatocyte antimicrobial programs controlling liver-stage malaria. First, oxidative defense by NADPH oxidases 2 and 4 triggers a pathway of lysosomal fusion with the parasitophorous vacuole (PV) to help clear Plasmodium. Second, guanylate-binding protein (GBP) 1-mediated disruption of the PV activates the caspase-1 inflammasome, inducing pyroptosis to remove infected host cells. Remarkably, both human and mouse hepatocytes enlist these cell-autonomous immune programs to eliminate Plasmodium, with their pharmacologic or genetic inhibition leading to profound malarial susceptibility in vivo. In addition to identifying IFN-I-mediated cell-autonomous immune circuits controlling Plasmodium infection in the hepatocytes, our study also extends the understanding of how non-immune cells are integral to protective immunity against malaria.

Camila Marques-da-Silva, Clyde Schmidt-Silva, Carson Bowers, Nana Appiah Essel Charles-Chess, Cristina Samuel, Justine C Shiau, Eui-Soon Park, Zhongyu Yuan, Bae-Hoon Kim, Dennis E Kyle, John T Harty, John D MacMicking, Samarchith P Kurup. Cell Host Microbe. 2025 Mar 25:S1931-3128(25)00091-5. doi: 10.1016/j.chom.2025.03.008.

PfFBXO1 is essential for inner membrane complex formation in Plasmodium falciparum during both asexual and transmission stages

Donna Huber on February 7, 2025

PfFBXO1 localization by immunofluorescence stained with anti-V5 (PfFBXO1)

Plasmodium species replicate via schizogony, which involves asynchronous nuclear divisions followed by semi-synchronous segmentation and cytokinesis. Successful segmentation requires a double-membranous structure known as the inner membrane complex (IMC). Here we demonstrate that PfFBXO1 (PF3D7_0619700) is critical for both asexual segmentation and gametocyte maturation. In Toxoplasma gondii, the FBXO1 homolog, TgFBXO1, is essential for the development of the daughter cell scaffold and a component of the daughter cell IMC. We demonstrate PfFBXO1 forming a similar IMC initiation scaffold near the apical region of developing merozoites and unilaterally positioned in gametocytes of P. falciparum. While PfFBXO1 initially localizes to the apical region of dividing parasites, it displays an IMC-like localization as segmentation progresses. Similarly, PfFBXO1 localizes to the IMC region in gametocytes. Following inducible knockout of PfFBXO1, parasites undergo abnormal segmentation and karyokinesis, generating inviable daughters. PfFBXO1-deficient gametocytes are abnormally shaped and fail to fully mature. Proteomic analysis identified PfSKP1 as one of PfBXO1’s stable interacting partners, while other major proteins included multiple IMC pellicle and membrane proteins. We hypothesize that PfFBXO1 is necessary for IMC biogenesis, chromosomal maintenance, vesicular transport, and ubiquitin-mediated translational regulation of proteins in both sexual and asexual stages of P. falciparum.

Sreelakshmi K Sreenivasamurthy, Carlos Gustavo Baptista, Christopher M West, Ira J Blader, Jeffrey D Dvorin. Commun Biol. 2025 Feb 7;8(1):190. doi: 10.1038/s42003-025-07619-6.

Screening the Global Health Priority Box against Plasmodium berghei liver stage parasites using an inexpensive luciferase detection protocol

Donna Huber on November 23, 2024

Optimization of conditions for a luciferase endpoint with in-house reagents (FLAR).

Background: Malaria, a disease caused by parasites of the genus Plasmodium, continues to impact many regions globally. The rise in resistance to artemisinin-based anti-malarial drugs highlights the need for new treatments. Ideally, new anti-malarials will kill the asymptomatic liver stages as well as the symptomatic blood stages. While blood stage screening assays are routine and efficient, liver stage screening assays are more complex and costly. To decrease the cost of liver stage screening, a previously reported luciferase detection protocol requiring only common laboratory reagents was adapted for testing against luciferase-expressing Plasmodium berghei liver stage parasites.

Methods: After optimizing cell lysis conditions, the concentration of reagents, and the density of host hepatocytes (HepG2), the protocol was validated with 28 legacy anti-malarials to show this simple protocol produces a stable signal useful for obtaining quality small molecule potency data similar to that obtained from a high content imaging endpoint. The protocol was then used to screen the Global Health Priority Box (GHPB) and confirm the potency of hits in dose-response assays. Selectivity was determined using a galactose-based, 72 h HepG2 assay to avoid missing mitochondrial-toxic compounds due to the Crabtree effect. Receiver-operator characteristic plots were used to retroactively characterize the screens’ predictive value.

Results: Optimal luciferase signal was achieved using a lower HepG2 seed density (5 × 103 cells/well of a 384-well microtitre plate) compared to many previously reported luciferase-based screens. While producing lower signal compared to a commercial alternative, this luciferase detection method was found much more stable, with a > 3 h half-life, and robust enough for producing dose-response plots with as few as 500 sporozoites/well. A screen of the GHPB resulted in 9 hits with selective activity against P. berghei liver schizonts, including MMV674132 which exhibited 30.2 nM potency. Retrospective analyses show excellent predictive value for both anti-malarial activity and cytotoxicity.

Conclusions: This method is suitable for high-throughput screening at a cost nearly 20-fold less than using commercial luciferase detection kits, thereby enabling larger liver stage anti-malarial screens and hit optimization make-test cycles. Further optimization of the hits detected using this protocol is ongoing.

Gia-Bao Nguyen, Caitlin A Cooper, Olivia McWhorter, Ritu Sharma, Anne Elliot, Anthony Ruberto, Rafael Freitas, Ashutosh K Pathak, Dennis E Kyle, Steven P Maher. Malar J. 2024 Nov 23;23(1):357. doi: 10.1186/s12936-024-05155-y.

β-Carboline-3-carboxamide Antimalarials: Structure-Activity Relationship, ADME-Tox Studies, and Resistance Profiling

Donna Huber on October 28, 2024

Graphical abstract

The development of parasite resistance to both artemisinin derivatives and their partner drugs jeopardizes the effectiveness of the artemisinin combination therapy. Thus, the discovery of new antimalarial drugs, with new mechanisms of action, is urgently needed. We recently disclosed that β-carboline 1a was orally efficacious in Plasmodium berghei-infected mice and that it showed low cross-resistance between susceptible Plasmodium falciparum and four different drug-resistant strains. In this report, we describe the synthesis and in vitro antimalarial evaluation of 91 new derivatives of 1a. The asexual blood stage growth inhibition data show a clear preference for a 3,4-dihalogenated, 3,5-dihalogenated, 3,4,5-trichloro-, or 4-trifluoromethyphenyl ring at the C1-position. The most potent compound, 3,4,5-trichlorophenyl-substituted 42a, is twice as potent as 1a. Six potent analogues were assessed for their drug-like properties, and four of these were subjected to in vitro barcoded cross-resistance profiling. Compounds 1a, 1m, 42a, and 42m showed no cross-resistance to 32 resistance mutations on the Dd2 genetic background and 10 resistance mutations on the 3D7 genetic background. These data suggest that compounds in this scaffold possess a novel mechanism of antimalarial action.

Jopaul Mathew, Bo Zhou, Reagan S Haney, Kevin A Kunz, Leticia S Do Amaral, Rudraneel Roy Chowdhury, Joshua H Butler, Haibo Li, Amarraj J Chakraborty, Anika Tabassum, Emily K Bremers, Emilio F Merino, Rachael Coyle, Marcus C S Lee, Delphine Baud, Stephen Brand, Maxim Totrov, Maria Belen Cassera, Paul R Carlier. ACS Infect Dis. 2024 Oct 28. doi: 10.1021/acsinfecdis.4c00653.

Researchers discover malaria gene needed to make pair of invasion organelles

Donna Huber on October 2, 2024

by Donna Huber

Vasant Muralidharan and his research group at the University of Georgia’s Center for Tropical and Emerging Global Diseases have uncovered the role of an essential protein in Plasmodium falciparum, the parasite that causes the deadliest form of malaria. The discovery offers new insights for vaccine and drug development.

The parasite that causes malaria was discovered more than 125 years ago, but much is still unknown about this complex, single-celled organism. Researchers in the University of Georgia’s Center for Tropical and Emerging Global Diseases, however, have uncovered the role of one of the parasite’s essential proteins, offering new insights for vaccine and drug development.

Plasmodium falciparum causes the deadliest form of malaria, a disease the World Health Organization estimates killed more than 600,000 people worldwide died in 2022. A large majority of those deaths were children under the age of 5.

Historically, the parasite has been difficult to study due to its complex lifecycle, which includes three stages. One occurs in the mosquito, while the liver and blood stages take place in humans. The blood stage is when the infected person exhibits symptoms of malaria.

In the blood stage, the parasite invades red blood cells (RBCs) where they replicate and can be transmitted to the mosquito. The receptor-ligand complexes that enable RBC invasion have been well-studied and it is one of the targets of anti-malarial vaccines currently in clinical trials. But questions still remain.

“How does the parasite know it has encountered a red blood cell?” asked Vasant Muralidharan, associate professor in Franklin College’s Department of Cellular Biology and leader of the Muralidharan Research Group, where the study took place.

Interested, the team took a closer look at a protein called RON11, which is sent to a pair of unique club-shaped secretory organelles known as the rhoptry (Greek for club) that houses proteins needed to invade the RBC.

Click play to listen to an excerpt of Vasant Muralidharan discussing the cellular mechanics of malaria infection.

“When we knocked out this protein, we found that the parasite could do everything it usually does – create a putative pore in the membrane of the RBC, send proteins needed for parasite invasion through this putative opening into the RBC – but the parasite itself cannot enter the red blood cell,” Muralidharan explained. “If a parasite cannot enter the red blood cell, the life cycle is interrupted and the parasite dies.”

And then things got really interesting.

“We found that the parasites lacking RON11 were only producing half the rhoptry proteins, which are used in invasion,” Muralidharan said.

While it is known that Plasmodium parasites have two rhoptry organelles, they are so teeny-tiny they have been relatively understudied due to a lack of proper tools. However, new tools and techniques are emerging. David Anaguano, a cellular biology graduate student who led the study, traveled on a Daniel G. Colley Training in Parasitology fellowship to the Absalon Laboratory at Indiana University School of Medicine to learn a new tool known as Ultrastructure Expansion Microscopy.

Vasant Muralidharan is an associate professor in Franklin College’s Department of Cellular Biology. (Photo by Lauren Corcino)

“Electron microscopy is labor intensive, and since it uses thin slices of the parasite you are never sure if what you’re looking for really isn’t there or just not in the slice of the sample you have,” Muralidharan said. “Expansion microscopy is like using light microscopy but with a special gel to expand the cell proportionately in all directions. Thus, you don’t get the distortion you would with just an enlarged cell and you can image the entire infected cell in all dimensions. It has been a real game changer.”

As reported in the PLoS Biology paper, the Muralidharan group generated for the first time a Plasmodium cell with only one rhoptry organelle when they removed RON11 from malaria parasites.

“It’s not unusual for an organism to have a backup copy, but we can see that the parasite can create the first rhoptry just fine – without defect – but the second one that should form during the end of the replication cycle never forms,” Muralidharan said. “Why is that?”

As it appears that this second rhoptry is needed for RBC invasion, understanding the mechanisms that control its development could open up new targets for vaccine and drug treatment discovery as well as answering crucial questions like whether the two rhoptries are identical.

“This has been a long unanswered question,” Muralidharan said. “Now with this RON11 knockout parasite that doesn’t form a second rhoptry, we have the tools to answer it.”